POCN Hem/Onc

Reduced-Dose Onivyde is Effective for Treatment of Advanced Pancreatic Cancer

| Categories: pocn-hem-onc

In a real-world study, dose reductions (DRs) of liposomal irinotecan (Onivyde) were effective and associated with improved clinical outcomes in the treatment of pancreatic cancer. Liposomal […]

Reduced-Dose Onivyde is Effective for Treatment of Advanced Pancreatic Cancer

Ian Murphy2021-02-12T18:13:23+00:00December 8th, 2020|POCN Hem/Onc|

Comments Off

Hem/Onc Roundup: Cancer’s Long-Term Impact, Lung Cancer Immunotherapy, and more

POCNnews2020-11-25T14:58:32+00:00November 20th, 2020|Hematology & Oncology, POCN Hem/Onc|

Comments Off

Brian Jonas, MD, Discusses FDA Approval of Venclexta® in Combination for the Treatment of Newly Diagnosed AML

POCNnews2020-11-25T14:58:26+00:00November 20th, 2020|Acute Myeloid Leukemia Condition Center, Hematology & Oncology, POCN Hem/Onc|

Comments Off

CNS Pharmaceuticals Announces FDA Filing for Investigational New Drug to Treat Glioblastoma

POCNnews2020-11-25T14:58:25+00:00November 19th, 2020|Hematology & Oncology, POCN Hem/Onc|

Comments Off

Persistent Poverty Correlated with Increased Cancer Mortality

POCNnews2020-10-07T02:08:13+00:00September 30th, 2020|POCN Hem/Onc|

Comments Off